Proactiveinvestors recommends
Additional Information
Market: ASX
Sector: Healthcare, Equipment & Services
EPIC: AHZ
Latest Price: A$0.04  (2.38% Ascending)
52-week High: A$0.05
52-week Low: A$0.02
Market Cap: A$44.51M
1 year chart
digital-look imported chart image
Deal AHZ Tax Free*
*subject to change and depends on individual circumstances.
1 day chart
digital-look imported chart image
Advertisement
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Allied Healthcare Group
www.alliedhealthcaregroup.com.au
Deal Allied Healthcare Group Tax Free* Losses can exceed
your initial deposit *subject to change and depends on individual circumstances.
Allied Healthcare Group (ASX: AHZ) is a diversified healthcare company focused on investing in next generation technologies, acquiring strategic assets to grow its product and service offerings and increasing sales revenue from its existing medical sales business.
Full Allied Healthcare Group profile here
Pdf

Allied Healthcare Group substantial shareholder The Metal Group moves to 17.84% interest

May 02 2012, 3:37am

Allied Healthcare Group (ASX: AHZ) substantial shareholder The Metal Group has increased its stake in the company to 17.84%.

The Metal Group acquired around 34.3 million additional shares at $0.028 per share for a total consideration of $959,760 on 27 April.

The purchase increased the investor’s stake by 3.15%.

Highlighting the rapid pace at which Allied Healthcare continues to meet milestones, the company recently increased its shareholding in Coridon after investing a further A$1 million. 

This is a strategic move for Allied Healthcare, giving the company a 44.4% share in Coridon and maintaining its focus on unique drug programs with global implications.

Coridon is rapidly advancing towards its Phase I study for a herpes vaccine and is making further progress on its Human Papillomavirus (HPV) therapeutic vaccine program.

Less than two weeks prior to announcing it had increased its stake in Coridon, Allied Healthcare revealed Coridon had gained access to vector technology that will improve the performance of its next generation of DNA vaccines.

Coridon has entered into a licence agreement with Nature Technology Corporation for the use of its safe, minimalised and antibiotic-free selection vectors.

Importantly, the use of this vector will improve the overall benefit of Coridon’s vaccine by driving the in vivo transcription and translation of the genetic material.

Allied Healthcare is also further proving the commercial benefits of its ADAPT® Tissue Engineering Process. 

In early April the company released positive 36-month post Phase II human clinical trial follow-up results of paediatric patients who were implanted with the CardioCel® cardiovascular patches during various corrective cardiac surgical procedures. 

CardioCel® is a collagenous-based bioprosthetic device, made of tissue derived from bovine pericardium and treated with the ADAPT® Tissue Engineering Process.

The follow up data further supports the data for subsidiary Celxcel’s technology, in particular the prevention of calcium build up in tissue post implantation.

 

Proactive Investors is a market leader in the investment news space, providing ASX “Small and Mid-cap” company news, research reports, StockTube videos and One2One Investor Forums.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.